Sutro Biopharma STRO Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's accrued expenses?
- Sutro Biopharma (STRO) reported accrued expenses of $5.35M in Q1 2026.
- How has Sutro Biopharma's accrued expenses changed year-over-year?
- Sutro Biopharma's accrued expenses decreased by 53.7% year-over-year, from $11.55M to $5.35M.
- What is the long-term trend for Sutro Biopharma's accrued expenses?
- Over 5 years (2020 to 2025), Sutro Biopharma's accrued expenses has grown at a 87.8% compound annual growth rate (CAGR), from $627K to $14.64M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.